


## Setiptiline-d<sub>3</sub>

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-32329S   |
| <b>CAS No.:</b>           | 1795024-97-3  |
| <b>Molecular Formula:</b> | C <sub>19</sub> H <sub>16</sub> D <sub>3</sub> N  |
| <b>Molecular Weight:</b>  | 264.38  |
| <b>Target:</b>            | 5-HT Receptor; Adrenergic Receptor; Isotope-Labeled Compounds                             |
| <b>Pathway:</b>           | GPCR/G Protein; Neuronal Signaling; Others  |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                    |  |
|--------------------|--|
| <b>Description</b> | Setiptiline-d <sub>3</sub> is the deuterium labeled Setiptiline. Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α <sub>2</sub> -adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT <sub>2A</sub> , 5-HT <sub>2C</sub> , and/or 5-HT <sub>3</sub> subtypes, as well as an H <sub>1</sub> receptor inverse agonist/antihistamine[1][2]. |
| <b>In Vitro</b>    | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.   |

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Yamada K, Furukawa T. [Behavioral effects of a new antidepressant, setiptiline]. *Nihon Yakurigaku Zasshi.* 1991 Jan;97(1):31-9.
- [3]. Kamimura M, Aoba A, Yamaguchi N et al. The effect of age on plasma level of setiptiline maleate in depressed patients. *Prog Neuropsychopharmacol Biol Psychiatry.* 1994 Oct;18(6):1015-26.
- [4]. Kuniyoshi M, Nakamura J, Miura C, Inanaga K. Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry.* 1994 Mar;18(2):339-46.
- [5]. Niho T, Ito C, Shibutani Y, Hashizume H, Yamaguchi K. [Pharmacological properties of MO-8282, a novel antidepressant]. *Nihon Yakurigaku Zasshi.* 1986 Oct;88(4):309-20.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA